- Home
- DXR vs GBIO Comparison
DXR vs GBIO Comparison
Compare DXR & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- GBIO
- Stock Information
- Founded
- DXR 1970
- GBIO 2016
- Country
- DXR United States
- GBIO United States
- Employees
- DXR N/A
- GBIO N/A
- Industry
- DXR Medical/Dental Instruments
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- GBIO Health Care
- Exchange
- DXR Nasdaq
- GBIO Nasdaq
- Market Cap
- DXR 36.4M
- GBIO 29.2M
- IPO Year
- DXR N/A
- GBIO 2020
- Fundamental
- Price
- DXR $9.49
- GBIO $0.36
- Analyst Decision
- DXR Strong Buy
- GBIO Strong Buy
- Analyst Count
- DXR 1
- GBIO 4
- Target Price
- DXR $25.00
- GBIO $7.33
- AVG Volume (30 Days)
- DXR 5.6K
- GBIO 907.1K
- Earning Date
- DXR 01-01-0001
- GBIO 08-06-2025
- Dividend Yield
- DXR N/A
- GBIO N/A
- EPS Growth
- DXR 86.16
- GBIO N/A
- EPS
- DXR 0.11
- GBIO N/A
- Revenue
- DXR $119,714.00
- GBIO $24,556,000.00
- Revenue This Year
- DXR N/A
- GBIO N/A
- Revenue Next Year
- DXR N/A
- GBIO N/A
- P/E Ratio
- DXR $82.80
- GBIO N/A
- Revenue Growth
- DXR N/A
- GBIO 146.47
- 52 Week Low
- DXR $6.55
- GBIO $0.30
- 52 Week High
- DXR $10.00
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- DXR 69.88
- GBIO 43.92
- Support Level
- DXR $8.68
- GBIO $0.35
- Resistance Level
- DXR $9.03
- GBIO $0.38
- Average True Range (ATR)
- DXR 0.47
- GBIO 0.03
- MACD
- DXR 0.03
- GBIO -0.00
- Stochastic Oscillator
- DXR 90.38
- GBIO 3.33
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.